Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13236
Abstract: The CANVAS Program identified the effect of canagliflozin on major adverse cardiovascular events (MACE) differed according to whether participants were using diuretics at study commencement. We sought to further evaluate this finding related to baseline… read more here.
Keywords: canvas program; renal outcomes; canvas; cardiovascular renal ... See more keywords
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
Sign Up to like & getrecommendations! Published in 2019 at "Diabetologia"
DOI: 10.1007/s00125-019-4839-8
Abstract: Aims/hypothesisThe primary analysis of the Canagliflozin cardioVascular Assessment Study (CANVAS) Program showed canagliflozin to have a beneficial effect on cardiovascular and renal outcomes in people with type 2 diabetes at high cardiovascular risk, but also… read more here.
Keywords: canvas program; amputation; risk; canagliflozin ... See more keywords
Abstract 4116975: Safety signals with SGLT2 inhibitor use in diabetic males with erythrocytosis, but not in females: Findings from the CANVAS Program and CREDENCE trial
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4116975
Abstract: Backgrounds: Mediation analyses have shown that an increase in hematocrit (Hct) levels significantly contributes to the cardiorenal benefits of SGLT2 inhibitors (SGLT2i). However, given the link between erythrocytosis and poor prognosis, concerns remain about whether… read more here.
Keywords: canagliflozin; canvas program; hct; primary outcome ... See more keywords
Overall Safety of Canagliflozin (CANA) in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-259-or
Abstract: CANA is an SGLT2 inhibitor that was generally well tolerated in 12 placebo (PBO) and active-controlled phase 3/4 trials (non-CANVAS studies [NCS]) for ≤104 weeks in a broad range of patients with type 2 diabetes… read more here.
Keywords: canvas program; cana; safety; program ... See more keywords